Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$5.25 USD
-0.03 (-0.54%)
Updated May 21, 2024 09:38 AM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
Aprea Therapeutics, Inc. [APRE]
Reports for Purchase
Showing records 41 - 57 ( 57 total )
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Insufficient Pipeline Progress Plus Financing Overhang Spell Further Trouble
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
No Further Clarity on Clinical Holds; Reit. Neutral and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Clinical Holds Add to the Negative Sentiment for Eprenetapopt; Reit Neutral and Lowering our PT to $4 from $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold In Line With Our Expectations, Giving Eprenetapopt Another Damaging Blow
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Though Eprenetapopt Combo Hits Primary Endpoint, We Remain Guarded
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eprenetapopt Advances on Multiple Fronts, While Investors Wait For Strong Signals
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Retrospective Look at Phase 3 MDS Trial Provides Some Insights Into Recent Failure
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Aprea Faces Steep Development Climb; Reit Neutral and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
While Eprenetapopt Phase 3 Failure is Bad, Road Ahead May Be Worse; REIT Neutral and Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress Overshadowed by Risk/Reward Profile; Reit Neutral and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continue to Believe the Risk/Reward Profile Is Unfavorable; Reit Neutral and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 and Clinical Trials: A Combo That Doesn''t Mix?
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department